Latest News - DermTech

Wednesday, February 21, 2018

New DermTech Research Validates Gene Expression Against High-Risk DNA Mutations Providing Objective Information for the Diagnosis of Melanoma

DermTech, Inc. presented a late breaking abstract -- “Validation of Noninvasive Gene Expression (PLA) Against High Risk Driver Mutations (BRAF, NRAS, and TERT) in Cutaneous Melanoma” -- a…

Read the full story

Thursday, January 04, 2018

DermTech Receives Health Canada Approval to Market PLA and Non-invasive Biopsy Kit

DermTech, Inc's licensee, DermTech Canada Inc., has received approval to market DermTech’s Pigmented Lesions Assay (PLA) and non-invasive biopsy kit for the detection of melanoma in Canada. …

Read the full story

Monday, October 23, 2017

Dr. Daniel Siegel Joins DermTech's Advisory Board

DermTech, Inc., appointed Daniel M. Siegel, MD, to its Scientific Advisory Board. Dr. Siegel is a Clinical Professor of Dermatology and former Director of the Procedural Dermatology Fellowship at SUNY…

Read the full story

Tuesday, September 12, 2017

DermTech Appoints Dr. Gerald Krueger to Scientific Advisory Board

DermTech, Inc. has appointed Gerald G. Krueger, MD, to its Scientific Advisory Board. Dr. Krueger is Professor of Dermatology and Edna Benning Presidential Endowed Chair at the University of Utah in S…

Read the full story

Thursday, April 27, 2017

Non-Invasive Pigmented Lesion Assay Almost Doubles Biopsy Specificity

Dermatologists who incorporate Dermtech’s noninvasive pigmented lesion assay will biopsy fewer benign pigmented skin lesions and miss fewer melanomas, according to a new study in JAMA Derma…

Read the full story